Here, you'll find Trailhead guides and tutorials, user guides, tip sheets, and implementation guides organized by topic. Stay informed about our training events and attend sessions relevant to your ...

A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its ...

Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities ...

Dexcom received FDA clearance in March for the first over-the-counter glucose monitor, called Stelo. It’s cleared for adults who don’t take insulin, including people with Type 2 diabetes. The wellness ...

The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into its glucose biosensor products.

Investors with a lot of money to spend have taken a bearish stance on DexCom DXCM. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Dec 23 (Reuters) - Abbott Laboratories (ABT.N), opens new tab and DexCom (DXCM.O), opens new tab said on Monday they have reached an agreement to settle all patent disputes between them related to ...

Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to resolve all outstanding patent litigation in the U.S ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate ...